Comparative Pharmacology
Head-to-head clinical analysis: JENCYCLA versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENCYCLA versus LEVORA 0 15 30 21.
JENCYCLA vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
8-12 hours; prolonged to 24 hours in severe hepatic impairment
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive